Thymoma: A multivariate analysis of factors predicting survival

Blumberg, David; Port, Jeffrey L.; Weksler, Benny; Delgado, Ruby; Rosaí, Juan; Bains, Manjit S.; Ginsberg, Robert J.; Martini, Nael; McCormack, Patricia; Rusch, Valerie W.; Burt, M.

doi:10.1016/0003-4975(95)00669-c

Cited by 357 publications

(283 citation statements)

References 27 publications

Supporting

Mentioning

244

Contrasting

Unclassified

Order By: Relevance

“…21,29 Patients with larger tumors appear to have worse prognoses. 11,17,21,48 In this study, tumors 48 cm had 22 were not able to confirm the prognostic impact of the 8 cm cutoff; this may be due to the fact that there were very few large tumors in their series.…”

Section: Discussioncontrasting

confidence: 57%

“…Although some promote and anticipate a benign clinical course for these tumors, 6,[12][13][14][15][16] others (ourselves included) consider all thymomas as potentially malignant neoplasms. [1][2]10,[17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34] Many prior studies have documented malignant behavior in types A and AB thymomas. In our retrospective study of 71 cases of types A and AB thymomas (37 cases with follow-up information available), 18 patients (nine each of types A and AB) developed recurrence and or metastases.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

WHO types A and AB thymomas: not always benign

Jain

Mehta

Henley³

et al. 2010

Modern Pathology

View full text Add to dashboard Cite

The 2004 WHO classification of thymic tumors recognizes five major subtypes of thymomas and thymic carcinoma. Subtypes A and AB thymomas are purported to be benign neoplasms, although prior studies have suggested a potential for malignant behavior. The purpose of this study was to assess the clinical behavior of A and AB thymomas identified from a large institutional pathologic database. A retrospective slide review of 500 thymic epithelial tumors identified 71 (B14%) cases of types A and AB thymomas. Clinical history and follow-up information were obtained through retrospective chart review. There were 38 and 33 cases of types A and AB thymomas, respectively. Complete follow-up data were available in 37 (52%) cases. Eighteen (49%) patients (type A, n ¼ 9 and type AB, n ¼ 9) had evidence of recurrent/metastatic disease at an average of 62 months (range from 6 to 244 months) after initial diagnosis. Survival curves for patients with types A and AB thymomas, with and without recurrences, show a statistically significant difference (P ¼ 0.001 and 0.005, respectively). Analysis of this large cohort confirms the potential for subtypes A and AB thymomas to show malignant behavior. Long-term clinical monitoring, therefore, appears to be justified in these cases. This study also shows the poor correlation between the WHO classification and tumor behavior

show abstract

Section: Discussioncontrasting

confidence: 57%

Section: Discussionmentioning

confidence: 99%

WHO types A and AB thymomas: not always benign

Jain

Mehta

Henley³

et al. 2010

Modern Pathology

View full text Add to dashboard Cite

show abstract

“…Peak age of onset in thymomas with MG is 4th to 5th decade and without MG peaks in 7th or 8th decade [13,14]. Nearly one half patients are asymptomatic and incidentally discovered on routine examination or investigation.…”

Section: Clinical Featuresmentioning

confidence: 99%

A Review of Thymic Tumors

Bushan

Sharma

Verma

2013

Indian J Surg Oncol

View full text Add to dashboard Cite

Thymic tumors represent 0.2-1.5 % of all malignancies with an incidence of 0.15 per 100,000 population. Thymic tumors are most common tumors of the anterior mediastinum accounting for 20 % of all mediastinal tumors and 50 % of all anterior mediastinal tumors. Over 90 % of all thymic tumors occur in anterior mediastinum, remainder occurring in neck or other mediastinal areas especially aortopulmonary window and retro cardiac area which are common sites for ectopic thymic tissues and possible explanation for failure in some cases of simple thymectomy to improve Myasthenia Gravis(MG). The aim of this review is to discuss histologic classification, diagnostic features, evaluation, management and prognosis of thymic tumors.

show abstract

“…1,2 The prognostic factors for thymoma have been studied by many clinicians and researchers to establish a strategy for the treatment of patients with these tumors, including surgical resection, radiation therapy, and chemotherapy. Staging according to the classification system of Masaoka et al, 3 which is based on invasion to the surrounding organs, 3 completeness of resection, 4 -7 association with myasthenia gravis, 8 -10 tumor size, 11 and involvement of the great vessels, 12 reportedly can determine the postoperative survival of patients with thymoma. At the same time, the prognostic relevance of the histologic classification of thymoma has been discussed intensively [13][14][15][16][17] but remains to be determined.…”

mentioning

confidence: 99%

The World Health Organization histologic classification system reflects the oncologic behavior of thymoma

Okumura

Ohta

Tateyama

et al. 2002

Cancer

552

414

View full text Add to dashboard Cite

BACKGROUNDAlthough the histologic classification of thymic epithelial tumors has been confusing and controversial, an agreement on the universal classification system for thymic epithelial tumors was achieved by the World Health Organization (WHO) in 1999. The authors previously reported that the WHO histologic classification system reflects invasiveness and immunologic function of thymic epithelial tumors. In this subsequent study, they examined the prognostic significance of this classification system.METHODSClinical features as well as postoperative survival of patients with thymoma, but not thymic carcinoma, were examined with reference to WHO histologic classification based on an experience with 273 patients over a 44‐year period.RESULTSThere were 18 type A tumors, 77 type AB tumors, 55 type B1 tumors, 97 type B2 tumors, and 26 type B3 tumors. In patients with type A, AB, B1, B2, and B3 tumors, the respective proportions of invasive tumor were 11.1%, 41.6%, 47.3%, 69.1%, and 84.6%; the respective proportions of tumors with involvement of the great vessels were 0%, 3.9%, 7.3%, 17.5%, and 19.2%; and the respective 20‐year survival rates were 100%, 87%, 91%, 59%, and 36%. According to the Masaoka staging system, the 20‐year survival rates were 89%, 91%, 49%, 0%, and 0% in patients with Stage I, II, III, IVa, and IVb disease, respectively. By multivariate analysis, the Masaoka staging system and the WHO histologic classification system were significant independent prognostic factors, whereas age, gender, association with myasthenia gravis, completeness of resection, or involvement of the great vessels were not significant independent prognostic factors.CONCLUSIONSThis study showed that histologic appearance reflects the oncologic behavior of thymoma when the WHO classification system is adopted. The WHO classification system may be helpful in clinical practice for the assessment and treatment of patients with thymoma. Cancer 2002;94:624–32. © 2002 American Cancer Society.DOI 10.1002/cncr.10225

show abstract

Thymoma: A multivariate analysis of factors predicting survival

Cited by 357 publications

References 27 publications

WHO types A and AB thymomas: not always benign

WHO types A and AB thymomas: not always benign

A Review of Thymic Tumors

The World Health Organization histologic classification system reflects the oncologic behavior of thymoma

Contact Info

Product

Resources

About